Adipogen/R-848/AG-CR1-3582-M005/5 mg
商品编号：
AG-CR1-3582-M005
品牌：
Adipogen Inc
市场价：
¥1000.00
美元价：
600.00
产品分类：
其他试剂
公司分类：
Other_reagents
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
| Product Details | |
|---|---|
| Synonyms | Resiquimod; S 28463; R848 |
| Product Type | Chemical |
| Properties | |
| Formula | C17H22N4O2 |
| MW | 314.4 |
| CAS | 144875-48-9 |
| Source/Host Chemicals | Synthetic. |
| Purity Chemicals | ≥98% |
| Appearance | White to off-white powder. |
| Solubility | Soluble in DMSO, dichloromethane or methanol. Slightly soluble in acetonitrile or ethyl acetate. |
| InChi Key | BXNMTOQRYBFHNZ-DZQCGVKKCS |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice |
After reconstitution, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles. |
| Use/Stability |
Stable for at least 2 years after receipt when stored at -20°C. Stock solutions are stable for at least 3 months when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
- Immune response modifier. Potent antitumor and antiviral compound [1, 3, 10, 11, 13, -16].
- Stimulates antibody secretion and cytokine production [2].
- Used as adjuvant to increase the effectiveness of vaccines [2, 7, 9, 10].
- Potent and selective synthetic ligand for Toll-like receptor 7 (TLR7) in mouse and for TLR7 and TLR8 in human [4-6].
- Activates immune cells via the TLR7/TLR8 MyD88-dependent signaling pathway and leads to the induction of NF-κB [4].
- NLRP3/NALP3 inflammasome activator, independent of TLRs and RIG-I [8].
- Upregulator of the opioid growth factor receptor [12].
- Used in the treatment of skin lesions such as herpes simplex virus [16].
Product References
- Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod: T.L. Wagner, et al.; Cell Immunol. 191, 10 (1999)
- Adjuvant activities of immune response modifier R-848: comparison with CpG ODN: J.P. Vasilakos, et al.; Cell Immunol. 204, 64 (2000)
- The immune response modifier resiquimod mimics CD40-induced B cell activation: G.A. Bishop, et al.; Cell. Immunol. 208, 9 (2001)
- Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway: H. Hemmi, et al.; Nat. Immunol. 3, 196 (2002)
- Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848: M. Jurk, et al.; Nat. Immunol. 3, 499 (2002)
- Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8: K.B. Gorden, et al.; J. Immunol. 174, 1259 (2005)
- TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848): R.D. Weeratna, et al.; Vaccine 23, 5263 (2005)
- Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3: T.D. Kanneganti, et al.; Nature 440, 233 (2006)
- Additive effects of CpG ODN and R-848 as adjuvants on augmenting immune responses to HBsAg vaccination: R. Ma, et al.; BBRC 361, 537 (2007)
- Resiquimod and other immune response modifiers as vaccine adjuvants: M.A. Tomai, et al.; Expert Rev. Vaccines 6, 835 (2007) (Review)
- The antiviral activity of Toll-like receptor 7 and 7/8 agonists: R.L. Miller, et al.; Drug News Perspect. 21, 69 (2008) (Review)
- Imiquimod upregulates the opioid growth factor receptor to inhibit cell proliferation independent of immune function: I.S. Zagon, et al.; Exp. Biol. Med. 233, 968 (2008)
- Targeting Toll-like receptor 7/8 enhances uptake of apoptotic leukemic cells by monocyte-derived dendritic cells but interferes with subsequent cytokine-induced maturation: W. van den Ancker, et al.; Cancer Immunol. Immunother. 60, 37 (2011)
- Treatment with the TLR7 agonist R848 induces regulatory T-cell-mediated suppression of established asthma symptoms: L.P. Van, et al.; Eur. J. Immunol. 41, 1992 (2011)
- R-848 triggers the expression of TLR7/8 and suppresses HIV replication in monocytes: H. Nian, et al.; BMC Infect. Dis. 12, 5 (2012)
- Resiquimod|a topical drug for viral skin lesions and skin cancer: T. Meyer, et al.; Expert Opin. Investig. Drugs 22, 149 (2013)
品牌介绍
Adipogen公司由三个子公司组成，分别是Adipogen,Inc.(韩国),AdipogenSA(瑞士)和 AdipogenCorporation(美国圣地亚哥)。总部设在美国，运营总部在瑞士利斯塔尔。Adipogen公司专门从事生命科学研究试剂的开发，如癌症、免疫、炎症、代谢疾病（糖尿病、肥胖）、干细胞和神经退行性疾病等领域。其重点关注开发创新优质的ELISA试剂盒。另外，也可提供抗体和蛋白产品，Adipogen拥有自己的化学实验室，致力于开发创新型小分子化合物。
联络我们
